Company: SNSE
Filing Date: 2025-04-01
Form Type: PRE 14A
Source: 0000950170-25-048533
Chunk: 46

Company: Sensei Biotherapeutics, Inc.
Filing Date: 2025-04-01
Form: PRE 14A
Chunk 46
---
 2018. Ms. Krebs also worked at Biogen Inc. in various roles of increasing responsibility from July 2006 to October 2016. She holds a Bachelor of Science in Microbiology and Immunology from the University of Rochester, a Master of Science in Biotechnology from Johns Hopkins University and an MBA from the William E. Simon Graduate School of Business Administration, University of Rochester.

<div align='center'>24

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</div>

The following table sets forth the beneficial ownership of our common stock as of March 18, 2025 for:

| • |     | each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock; |
| • |     | each of our named executive officers;                                                                                 |
| • |     | each of our directors; and                                                                                            |
| • |     | all of our executive officers and directors as a group.                                                               |

We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those securities. In addition, these rules require that we include shares of common stock issuable pursuant to the vesting of restricted stock units and the exercise of stock options that are either immediately exercisable or exercisable within 60 days of March 18, 2025. These shares are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person.

Except as otherwise noted below, the address for persons listed in the table is c/o Sensei Biotherapeutics, Inc., 1405 Research Blvd, Suite 125, Rockville, Maryland 20850.

| Name                                                                |     | Number of Shares Beneficially Owned |           |     | Percent of Shares Beneficially Owned (1) |      |     |   |
| Greater than 5% Stockholders:                                       |     |                                     |           |     |                                          |      |     |   |
| Cambrian BioPharma Inc. (2)                                         |     |                                     | 3,719,156 |     |                                          | 14.7 |     | % |
| H&S Investments I LP (3)                                            |     |                                     | 4,441,624 |